Exciting news for those affected by progressive pulmonary fibrosis (PPF): The US FDA has granted approval for Jascayd (nerandomilast). This...
Progressive
Nerandomilast (BI 1015550) is an investigational oral drug that selectively inhibits phosphodiesterase 4B, exhibiting antifibrotic and immune-modulating effects. In previous...
Nerandomilast met its primary end point of absolute change from baseline in forced vital capacity (FVC) vs placebo in the...
